Potenza Therapeutics is a cancer immunotherapy startup focused on development of novel biologic agents targeting immune regulatory pathways. The company’s public descriptions emphasize therapies that act on immune checkpoints and emerging immune regulatory targets. It is MPM Capital-backed and led by Daniel Hicklin, a managing director at MPM Capital. Potenza is housed in LabCentral in Cambridge’s Kendall Square and has applied for a biosafety permit as it prepares to move into new lab space at 1030 Massachusetts Ave. The company has been hiring for scientific roles, including a principal scientist, reflecting early R&D buildout. Financially, Potenza recently raised capital per a regulatory filing and is pursuing further development of its immunotherapy programs.

Total raised

$15M

Funding rounds

2

Latest round

Equity

Latest activity

Dec 2014